Bio News
G2G Bio disclosed the final results of the Phase 1 trial of GB-5001A, a candidate treatment for Alzheimer disease dementia. After four intramuscular injections of 140 mg at 4-week intervals, steady-state levels were reached within three to four doses. G2G Bio plans to conduct follow-up clinical studies based on these results.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
